{"id":"placebo-inhalation-solution-qd","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo is an inert substance used as a control in clinical trials. Any observed clinical benefit derives from patient expectation, the therapeutic context, and psychobiological mechanisms rather than direct drug action. In Phase 3 trials, placebo serves as the comparator to establish the efficacy of the investigational active agent.","oneSentence":"Placebo has no active pharmacological mechanism and produces therapeutic effects solely through the placebo effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:44.525Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07450482","phase":"PHASE2","title":"Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2025-07-22","conditions":"COPD (Chronic Obstructive Pulmonary Disease), COPD","enrollment":42},{"nctId":"NCT07439419","phase":"PHASE1","title":"DBM-1152A Inhalation Solution in Healthy Volunteers","status":"COMPLETED","sponsor":"Joincare Pharmaceutical Group Industry Co., Ltd","startDate":"2024-08-18","conditions":"Healthy","enrollment":20},{"nctId":"NCT00677365","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-06","conditions":"Cystic Fibrosis (CF)","enrollment":151},{"nctId":"NCT05046795","phase":"PHASE3","title":"Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)","status":"COMPLETED","sponsor":"Mylan Pharma UK Ltd.","startDate":"2021-11-10","conditions":"COPD","enrollment":258},{"nctId":"NCT04903730","phase":"PHASE1","title":"Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution","status":"COMPLETED","sponsor":"Aerami Therapeutics","startDate":"2021-05-24","conditions":"Pulmonary Arterial Hypertension","enrollment":83},{"nctId":"NCT02109172","phase":"PHASE2","title":"A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2014-04","conditions":"Chronic Obstructive Pulmonary Disease, COPD","enrollment":64},{"nctId":"NCT04187508","phase":"PHASE2","title":"A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen","status":"WITHDRAWN","sponsor":"AstraZeneca","startDate":"2020-02-06","conditions":"Asthma","enrollment":""},{"nctId":"NCT02478398","phase":"PHASE3","title":"Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-07-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1025},{"nctId":"NCT03118765","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2017-03-24","conditions":"Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)","enrollment":155},{"nctId":"NCT01634139","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":403},{"nctId":"NCT01634152","phase":"PHASE3","title":"Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2012-07","conditions":"Asthma","enrollment":401},{"nctId":"NCT00685841","phase":"PHASE3","title":"A Pivotal Study of the Safety and Effectiveness of Arformoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-02","conditions":"COPD","enrollment":717},{"nctId":"NCT00064402","phase":"PHASE3","title":"Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-04","conditions":"Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema","enrollment":741},{"nctId":"NCT00691405","phase":"PHASE2","title":"A Dose Ranging Study of Arformoterol Given Once Daily Compared to Arformoterol Given Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2003-10","conditions":"COPD","enrollment":215},{"nctId":"NCT00571428","phase":"PHASE4","title":"Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo inhalation solution QD","genericName":"Placebo inhalation solution QD","companyName":"Mylan Pharma UK Ltd.","companyId":"mylan-pharma-uk-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}